Oncolytics Biotech Advances Pancreatic Cancer Treatment with Regulatory Approval

Oncolytics Biotech ( (TSE:ONC) ) just unveiled an announcement.

Oncolytics Biotech has received regulatory approval from Germany’s Paul-Ehrlich-Institute to proceed with the full enrollment of Cohort 5 in their GOBLET study, which evaluates the combination of pelareorep and mFOLFIRINOX, with or without atezolizumab, for pancreatic ductal adenocarcinoma patients. This approval follows a favorable safety review, and early safety data will be presented at the upcoming 2025 ASCO Symposium. The progression of this cohort could potentially expand treatment options for metastatic pancreatic cancer patients, significantly impacting Oncolytics’ position in the oncology market.

More about Oncolytics Biotech

Oncolytics Biotech Inc. is a clinical-stage biotechnology company focused on developing pelareorep, an intravenously delivered immunotherapeutic agent. The company is engaged in clinical trials for treating various cancers, including metastatic breast cancer and pancreatic cancer, utilizing pelareorep’s ability to induce anti-cancer immune responses and enhance tumor inflammation.

YTD Price Performance: -12.90%

Average Trading Volume: 460,901

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $62.81M

For a thorough assessment of ONC stock, go to TipRanks’ Stock Analysis page.